Remove Diabetes Remove Labelling Remove Pharmaceutical Companies
article thumbnail

Social Media Marketing Strategies Working in Pharma

Pharma Marketing Network

In the digital-first era, social media marketing strategies are reshaping how pharmaceutical companies engage with healthcare professionals, patients, and caregivers. This approach builds credibility and humanizes the company. These strategies are no longer optional; they are essential. Platforms must be leveraged carefully.

article thumbnail

PPC Campaign Optimization for Pharma: Boosting ROI

Pharma Marketing Network

Introduction Pharmaceutical companies are investing heavily in digital advertising , and PPC campaign optimization is key to maximizing ROI while staying compliant. diabetes, cancer). No unapproved drug claims All claims must be backed by clinical research and FDA-approved labeling.

HIPAA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. In 2022, based upon a complaint filed by a pharmaceutical company, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said.

article thumbnail

Advanced Solutions for Sustained Delivery of Ocular Therapies

PharmaTech

Pharmaceutical companies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-related Blindness.

Dosage 64
article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Dive

Based on conversations with physicians, it “could be positioned well, and ahead of Augtyro,” he wrote, adding that Wednesday’s sell off in shares was “overdone on any potential launch and label optics concerns.”

article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Why security-first design is the fix to stalling AI pilot tools

pharmaphorum

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)